1. Academic Validation
  2. ROS Reduction Does Not Decrease the Anticancer Efficacy of X-Ray in Two Breast Cancer Cell Lines

ROS Reduction Does Not Decrease the Anticancer Efficacy of X-Ray in Two Breast Cancer Cell Lines

  • Oxid Med Cell Longev. 2019 Mar 14;2019:3782074. doi: 10.1155/2019/3782074.
Huizhen Wang 1 2 Xin Zhang 1 3
Affiliations

Affiliations

  • 1 High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China.
  • 2 University of Science and Technology of China, Hefei, Anhui 230036, China.
  • 3 Institute of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601, China.
Abstract

Radiotherapy is effective on a large number of Cancer types and is one of the most frequently administrated treatments for Cancer patients. The Anticancer efficacy of X-ray radiotherapy has been frequently correlated with Reactive Oxygen Species (ROS) elevation, which is also a limiting factor for its toxicity on normal tissues. Here, we found that although 4-10 Gy X-rays could significantly reduce cell numbers in both MDA-MB-231 and MCF-7 breast Cancer cells, the ROS level changes are less in MCF-7 cells than in MDA-MB-231 cells. Moreover, although both the ROS scavenger N-acetyl-L-cysteine (NAC) and 1 T static magnetic field (SMF) could reduce X-ray-induced ROS elevation, they did not prevent X-ray-induced cell number reduction or cell death increase, which is significantly different from cisplatin. These results demonstrate that although the Anticancer efficacy of cisplatin on two breast Cancer cell lines is dependent on ROS, the Anticancer efficacy of X-ray is not. Moreover, by testing 19 different cell lines, we found that 1 T SMF could effectively reduce ROS levels in multiple cell lines by 10-20%, which encourages further studies to investigate whether SMF could be used as a potential "physical antioxidant" in the future.

Figures
Products